|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q110682405
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241120235947.0 |
|
008
|
|
|
241120nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q110682405
|
|
024
|
|
|
‡a
0000-0003-3303-9406
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q110682405
|
|
100
|
0 |
|
‡a
John P. Roberts
‡c
liver transplantation surgery researcher at UCSF
‡9
en
|
|
670
|
|
|
‡a
Author's 3D T2-weighted and Gd-EOB-DTPA-enhanced 3D T1-weighted MR cholangiography for evaluation of biliary anatomy in living liver donors
|
|
670
|
|
|
‡a
Author's A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function
|
|
670
|
|
|
‡a
Author's A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy
|
|
670
|
|
|
‡a
Author's A Formula to Calculate Standard Liver Volume Using Thoracoabdominal Circumference.
|
|
670
|
|
|
‡a
Author's A modified vascular "sleeve" anastomosis for rearterialization in orthotopic liver transplantation in rats
|
|
670
|
|
|
‡a
Author's A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival
|
|
670
|
|
|
‡a
Author's A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
|
|
670
|
|
|
‡a
Author's A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
|
|
670
|
|
|
‡a
Author's A virtual crossmatch based strategy facilitates sharing of deceased donor kidneys for highly sensitized recipients
|
|
670
|
|
|
‡a
Author's A2 liver transplantation across the ABO barrier: Increasing options in the donor pool?
|
|
670
|
|
|
‡a
Author's ABO-Nonidentical Liver Transplantation in the United States
|
|
670
|
|
|
‡a
Author's Accuracy of Doppler-estimated pulmonary vascular resistance in patients before liver transplantation
|
|
670
|
|
|
‡a
Author's Accuracy of plain abdominal radiographs in the detection of retained surgical needles in the peritoneal cavity
|
|
670
|
|
|
‡a
Author's Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin
|
|
670
|
|
|
‡a
Author's Acute liver transplantation rejection. Early detection of endothelial leak in a rat model using magnetic resonance imaging and a macromolecular contrast medium.
|
|
670
|
|
|
‡a
Author's Adult living donor liver imaging
|
|
670
|
|
|
‡a
Author's Allograft rejection in pediatric liver transplantation: Comparison between cadaveric and living related donors
|
|
670
|
|
|
‡a
Author's Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes
|
|
670
|
|
|
‡a
Author's Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria
|
|
670
|
|
|
‡a
Author's Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma
|
|
670
|
|
|
‡a
Author's American Society of Transplant Surgeons transplant center outcomes requirements--a threat to innovation
|
|
670
|
|
|
‡a
Author's An eye to quality
|
|
670
|
|
|
‡a
Author's An older liver in the hand, or a (possibly) younger liver in the bush?
|
|
670
|
|
|
‡a
Author's Anastomosing hemangioma of liver
|
|
670
|
|
|
‡a
Author's Anesthetic Care of Patients With Crigler-Najjar Syndrome
|
|
670
|
|
|
‡a
Author's Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection.
|
|
670
|
|
|
‡a
Author's Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.
|
|
670
|
|
|
‡a
Author's Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?
|
|
670
|
|
|
‡a
Author's Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol
|
|
670
|
|
|
‡a
Author's ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation
|
|
670
|
|
|
‡a
Author's Author response: reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis
|
|
670
|
|
|
‡a
Author's Auxiliary Liver Transplant in Fulminant Failure
|
|
670
|
|
|
‡a
Author's Bi-organ paired exchange-Sentinel case of a liver-kidney swap
|
|
670
|
|
|
‡a
Author's Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list
|
|
670
|
|
|
‡a
Author's Biliary complications after liver transplantation in children
|
|
670
|
|
|
‡a
Author's Biliary complications following living donor hepatectomy
|
|
670
|
|
|
‡a
Author's Biliary complications of reduced-organ liver transplantation
|
|
670
|
|
|
‡a
Author's Biliary tract depiction in living potential liver donors: comparison of conventional MR, mangafodipir trisodium-enhanced excretory MR, and multi-detector row CT cholangiography--initial experience
|
|
670
|
|
|
‡a
Author's Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial
|
|
670
|
|
|
‡a
Author's CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients
|
|
670
|
|
|
‡a
Author's Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes
|
|
670
|
|
|
‡a
Author's Central venous pressure monitoring during living right donor hepatectomy
|
|
670
|
|
|
‡a
Author's Chain transplantation: initial experience of a large multicenter program
|
|
670
|
|
|
‡a
Author's Characterization of a cyclosporine-containing liposome
|
|
670
|
|
|
‡a
Author's Characterization of distal colonic motility in early postoperative period and effect of colonic anastomosis
|
|
670
|
|
|
‡a
Author's Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case
|
|
670
|
|
|
‡a
Author's Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation
|
|
670
|
|
|
‡a
Author's Comparison of biliary complications in adult living-donor liver transplants performed at two busy transplant centers
|
|
670
|
|
|
‡a
Author's Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens
|
|
670
|
|
|
‡a
Author's Comparison of three regimens for cytomegalovirus prophylaxis in 147 liver transplant recipients.
|
|
670
|
|
|
‡a
Author's Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants
|
|
670
|
|
|
‡a
Author's Concordance of second-order portal venous and biliary tract anatomies on MDCT angiography and MDCT cholangiography
|
|
670
|
|
|
‡a
Author's Consensus-based perioperative protocols during the COVID-19 pandemic
|
|
670
|
|
|
‡a
Author's Consumerist responses to scarcity of organs for transplant
|
|
670
|
|
|
‡a
Author's Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center
|
|
670
|
|
|
‡a
Author's Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma
|
|
670
|
|
|
‡a
Author's Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation
|
|
670
|
|
|
‡a
Author's Cost of Organ Procurement and Transplantation Network Data Collection for a Large Transplant Center
|
|
670
|
|
|
‡a
Author's COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions
|
|
670
|
|
|
‡a
Author's Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients
|
|
670
|
|
|
‡a
Author's Cryoglobulinemia presenting after liver transplantation
|
|
670
|
|
|
‡a
Author's CT cholangiography in potential liver donors: effect of premedication with intravenous morphine on biliary caliber and visualization
|
|
670
|
|
|
‡a
Author's Cytokine and T cell receptor gene expression at the site of allograft rejection
|
|
670
|
|
|
‡a
Author's De novo malignancies following liver transplantation: a case-control study with long-term follow-up
|
|
670
|
|
|
‡a
Author's Decreased mortality from technical failure improves results in pediatric liver transplantation
|
|
670
|
|
|
‡a
Author's Delayed Graft Function and Acute Rejection Following HLA-Incompatible Living Donor Kidney Transplantation
|
|
670
|
|
|
‡a
Author's Demonstration of local immunosuppression with methylprednisolone in the sponge matrix allograft model
|
|
670
|
|
|
‡a
Author's Determinants of second-order bile duct visualization at CT cholangiography in potential living liver donors
|
|
670
|
|
|
‡a
Author's Development of a novel frailty index to predict mortality in patients with end-stage liver disease
|
|
670
|
|
|
‡a
Author's Disability in patients with end-stage liver disease: Results from the functional assessment in liver transplantation study.
|
|
670
|
|
|
‡a
Author's Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria
|
|
670
|
|
|
‡a
Author's Do preoperative inflammatory markers impact on outcome after liver transplantation for hepatocellular carcinoma?
|
|
670
|
|
|
‡a
Author's Donor health assessment after living-donor liver transplantation
|
|
670
|
|
|
‡a
Author's Donor Liver Small Droplet Macrovesicular Steatosis Is Associated With Increased Risk for Recipient Allograft Rejection
|
|
670
|
|
|
‡a
Author's Donor selection limits use of living-related liver transplantation
|
|
670
|
|
|
‡a
Author's Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria
|
|
670
|
|
|
‡a
Author's Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups
|
|
670
|
|
|
‡a
Author's Effect of cisapride on distal colonic motility in the early postoperative period following left colonic anastomosis
|
|
670
|
|
|
‡a
Author's Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients.
|
|
670
|
|
|
‡a
Author's Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease
|
|
670
|
|
|
‡a
Author's Endovascular closure of a portocaval shunt after left lobe liver transplantation using an Amplatzer muscular ventricular septal occluder device
|
|
670
|
|
|
‡a
Author's Enterococcal bacteremia after transjugular intrahepatic portosystemic shunts (TIPS).
|
|
670
|
|
|
‡a
Author's Ethical issues in split versus whole liver transplantation
|
|
670
|
|
|
‡a
Author's Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm
|
|
670
|
|
|
‡a
Author's Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils.
|
|
670
|
|
|
‡a
Author's Ex vivo split-liver transplantation: the true right/left split
|
|
670
|
|
|
‡a
Author's Examination of vascular anastomoses during liver transplantation by intraoperative Doppler duplex scanning.
|
|
670
|
|
|
‡a
Author's Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis
|
|
670
|
|
|
‡a
Author's Excellent Outcomes of Liver Transplantation Following Down Staging of Hepatocellular Carcinoma to Within Milan Criteria-a Multi-Center Study
|
|
670
|
|
|
‡a
Author's Expanded criteria donor kidney allocation: marked decrease in cold ischemia and delayed graft function at a single center
|
|
670
|
|
|
‡a
Author's Expanding Living Donor Liver Transplantation: Report of First United States Living Donor Liver Transplant Chain
|
|
670
|
|
|
‡a
Author's Expanding the Donor Pool: Can the Spanish Model Work in the United States?
|
|
670
|
|
|
‡a
Author's Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation
|
|
670
|
|
|
‡a
Author's Experience with laparoscopic donor nephrectomy among more than 1000 cases: low complication rates, despite more challenging cases
|
|
670
|
|
|
‡a
Author's Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated
|
|
670
|
|
|
‡a
Author's Factors influencing liver transplant length of stay at two large-volume transplant centers
|
|
670
|
|
|
‡a
Author's Failure patterns of cryopreserved vein grafts in liver transplantation
|
|
670
|
|
|
‡a
Author's Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants.
|
|
670
|
|
|
‡a
Author's Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.
|
|
670
|
|
|
‡a
Author's Frequent salvage of ruptured renal allografts: a large single center experience
|
|
670
|
|
|
‡a
Author's Functional analysis of grafts from living donors. Implications for the treatment of older recipients.
|
|
670
|
|
|
‡a
Author's Gender differences in liver donor quality are predictive of graft loss
|
|
670
|
|
|
‡a
Author's Geographic Disparity in Liver Allocation: Time to Act or Have Others Act for us.
|
|
670
|
|
|
‡a
Author's Graft vs. host disease after liver transplantation in humans: A report of four cases
|
|
670
|
|
|
‡a
Author's Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization.
|
|
670
|
|
|
‡a
Author's Hepatic artery pseudoaneurysm with hemobilia following angioplasty after liver transplantation
|
|
670
|
|
|
‡a
Author's Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors.
|
|
670
|
|
|
‡a
Author's Hepatic granulomas following liver transplantation. Clinicopathologic features in 42 patients.
|
|
670
|
|
|
‡a
Author's Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus
|
|
670
|
|
|
‡a
Author's Hepatitis after liver transplantation: the role of the known and unknown viruses.
|
|
670
|
|
|
‡a
Author's Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy
|
|
670
|
|
|
‡a
Author's Hepatitis C Virus Not Found in Fulminant Non-A, Non-B Hepatitis
|
|
670
|
|
|
‡a
Author's Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantation
|
|
670
|
|
|
‡a
Author's Hepatocellular carcinoma: Ablate and wait versus rapid transplantation
|
|
670
|
|
|
‡a
Author's Hepatotoxins and liver transplantation decrease pulmonary metastases in rats with hepatoma
|
|
670
|
|
|
‡a
Author's High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome
|
|
670
|
|
|
‡a
Author's Histopathologic study of transjugular intrahepatic portosystemic shunts
|
|
670
|
|
|
‡a
Author's History of marijuana use does not affect outcomes on the liver transplant waitlist
|
|
670
|
|
|
‡a
Author's HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes
|
|
670
|
|
|
‡a
Author's Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study
|
|
670
|
|
|
‡a
Author's IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro
|
|
670
|
|
|
‡a
Author's Image of the month. Portal hypertensive biliopathy.
|
|
670
|
|
|
‡a
Author's Impact of a quality improvement project on deceased organ donor management
|
|
670
|
|
|
‡a
Author's Impact of Graft Selection on Donor and Recipient Outcomes After Living Donor Liver Transplantation
|
|
670
|
|
|
‡a
Author's Impact of preclinical exposure to organ donation on knowledge and attitudes of medical students.
|
|
670
|
|
|
‡a
Author's Impact of the Pediatric End-Stage Liver Disease (PELD) growth failure thresholds on mortality among pediatric liver transplant candidates
|
|
670
|
|
|
‡a
Author's Improving liver allocation: MELD and PELD.
|
|
670
|
|
|
‡a
Author's Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.
|
|
670
|
|
|
‡a
Author's Incidence and significance of Aspergillus cultures following liver and kidney transplantation
|
|
670
|
|
|
‡a
Author's Increased efficacy of CSA following rearterialization in the rat OLTX model
|
|
670
|
|
|
‡a
Author's Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant
|
|
670
|
|
|
‡a
Author's Increased severity of renal ischemia-reperfusion injury with venous clamping compared to arterial clamping in a rat model
|
|
670
|
|
|
‡a
Author's Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
|
|
670
|
|
|
‡a
Author's Influence of graft type on outcomes after pediatric liver transplantation
|
|
670
|
|
|
‡a
Author's Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing
|
|
670
|
|
|
‡a
Author's Interferon alfa for recurrent hepatitis B infection after liver transplantation
|
|
670
|
|
|
‡a
Author's International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients
|
|
670
|
|
|
‡a
Author's Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure
|
|
670
|
|
|
‡a
Author's Intragraft cytokine profile during human liver allograft rejection
|
|
670
|
|
|
‡a
Author's Intragraft eosinophilia and interleukin-5 mRNA accompany liver allograft rejection.
|
|
670
|
|
|
‡a
Author's Intrahepatic portocaval shunt for variceal hemorrhage prior to liver transplantation.
|
|
670
|
|
|
‡a
Author's Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
|
|
670
|
|
|
‡a
Author's Intraoperative hemodynamics and liver function in adult-to-adult living liver donors
|
|
670
|
|
|
‡a
Author's Ischemia-reperfusion injury is more severe in older versus young rat livers.
|
|
670
|
|
|
‡a
Author's Ischemic preconditioning improves energy state and transplantation survival in obese Zucker rat livers
|
|
670
|
|
|
‡a
Author's Isolation of functional MHC class I-deficient islet cells.
|
|
670
|
|
|
‡a
Author's Justifying Nonstandard Exception Requests for Pediatric Liver Transplant Candidates: An Analysis of Narratives Submitted to the United Network for Organ Sharing, 2009-2014.
|
|
670
|
|
|
‡a
Author's Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study
|
|
670
|
|
|
‡a
Author's Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
|
|
670
|
|
|
‡a
Author's Laparoscopic procurement of kidneys with multiple renal arteries is associated with increased ureteral complications in the recipient
|
|
670
|
|
|
‡a
Author's Laparoscopic right donor nephrectomy: a large single-center experience
|
|
670
|
|
|
‡a
Author's Left lobe adult-to-adult living donor liver transplantation: small grafts and hemiportocaval shunts in the prevention of small-for-size syndrome
|
|
670
|
|
|
‡a
Author's Live Donor Liver Transplantation in the United States: Impact of Share 35 on Live Donor Utilization
|
|
670
|
|
|
‡a
Author's Liver allocation and distribution: possible next steps.
|
|
670
|
|
|
‡a
Author's Liver and intestine transplantation
|
|
670
|
|
|
‡a
Author's Liver transplantation at the University of California, San Francisco
|
|
670
|
|
|
‡a
Author's Liver transplantation at UCSF--a 20-year experience.
|
|
670
|
|
|
‡a
Author's Liver transplantation complicated by malpositioned transjugular intrahepatic portosystemic shunts.
|
|
670
|
|
|
‡a
Author's Liver transplantation for autoimmune hepatitis: rejection and recurrence
|
|
670
|
|
|
‡a
Author's Liver transplantation for fulminant hepatic failure
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization.
|
|
670
|
|
|
‡a
Author's Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging
|
|
670
|
|
|
‡a
Author's Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference
|
|
670
|
|
|
‡a
Author's Liver transplantation for sclerosing cholangitis
|
|
670
|
|
|
‡a
Author's Liver transplantation for severe Amanita phalloides mushroom poisoning
|
|
670
|
|
|
‡a
Author's Liver transplantation improves survival of rats bearing hepatoma-3924A.
|
|
670
|
|
|
‡a
Author's Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Liver transplantation today
|
|
670
|
|
|
‡a
Author's Living donor candidates for right hepatic lobe transplantation: evaluation at CT cholangiography--initial experience
|
|
670
|
|
|
‡a
Author's Living Donor Liver Transplant for Alcoholic Liver Disease: Data from the Adult-to-adult Living Donor Liver Transplantation Study
|
|
670
|
|
|
‡a
Author's Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations
|
|
670
|
|
|
‡a
Author's Living related donor liver transplantation: the UCSF experience
|
|
670
|
|
|
‡a
Author's Long-term complications of living donor liver transplantation
|
|
670
|
|
|
‡a
Author's Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection
|
|
670
|
|
|
‡a
Author's Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database
|
|
670
|
|
|
‡a
Author's Long-term renal function and cardiovascular disease risk in obese kidney donors
|
|
670
|
|
|
‡a
Author's Maintenance immunosuppression after liver transplantation
|
|
670
|
|
|
‡a
Author's Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation.
|
|
670
|
|
|
‡a
Author's Major histocompatibility complex class I deficiency prolongs islet allograft survival.
|
|
670
|
|
|
‡a
Author's Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years
|
|
670
|
|
|
‡a
Author's Managing finances of shipping living donor kidneys for donor exchanges
|
|
670
|
|
|
‡a
Author's Massive venous air embolism during orthotopic liver transplantation
|
|
670
|
|
|
‡a
Author's Metabolic profiling of livers and blood from obese Zucker rats
|
|
670
|
|
|
‡a
Author's MHC expression on human hepatocytes before and after isolation
|
|
670
|
|
|
‡a
Author's Mild hypothermia protects obese rats from fulminant hepatic necrosis induced by ischemia-reperfusion.
|
|
670
|
|
|
‡a
Author's Mild hypothermia provides significant protection against ischemia/reperfusion injury in livers of obese and lean rats
|
|
670
|
|
|
‡a
Author's Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
|
|
670
|
|
|
‡a
Author's Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
|
|
670
|
|
|
‡a
Author's Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Moving kidney allocation forward: the ASTS perspective
|
|
670
|
|
|
‡a
Author's Multidisciplinary management of hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Multiple listings as a reflection of geographic disparity in liver transplantation
|
|
670
|
|
|
‡a
Author's Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation.
|
|
670
|
|
|
‡a
Author's Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients
|
|
670
|
|
|
‡a
Author's New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection.
|
|
670
|
|
|
‡a
Author's Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates
|
|
670
|
|
|
‡a
Author's Nonoperative management of biliary leaks after orthotopic liver transplantation
|
|
670
|
|
|
‡a
Author's Nonstandard Exception Requests Impact Outcomes for Pediatric Liver Transplant Candidates
|
|
670
|
|
|
‡a
Author's "Occult" hepatitis B virus as source of infection in liver transplant recipients
|
|
670
|
|
|
‡a
Author's Offer patterns of nationally placed livers by donation service area
|
|
670
|
|
|
‡a
Author's Opioid use prior to liver transplant is associated with increased risk of death after transplant
|
|
670
|
|
|
‡a
Author's Oral [111In]DTPA scintigraphic assessment of colonic transit in constipated subjects.
|
|
670
|
|
|
‡a
Author's Organ donation after cardiac death in amyotrophic lateral sclerosis
|
|
670
|
|
|
‡a
Author's Orthotopic liver transplantation for end-stage alcoholic liver disease.
|
|
670
|
|
|
‡a
Author's Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
|
|
670
|
|
|
‡a
Author's Outcomes of surgical repair of bile leaks and strictures after adult-to-adult living donor liver transplant
|
|
670
|
|
|
‡a
Author's Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010.
|
|
670
|
|
|
‡a
Author's Overdilation of a 6-mm Self-Expanding Stent with a 10-mm Balloon-Expandable Stent Graft Preserves Failing Meso-Rex Bypass
|
|
670
|
|
|
‡a
Author's Patient, center and geographic characteristics of nationally placed livers
|
|
670
|
|
|
‡a
Author's Patterns of Early Allograft Dysfunction in Adult Live Donor Liver Transplantation: The A2ALL Experience.
|
|
670
|
|
|
‡a
Author's Percutaneous salvage of a failing rex shunt
|
|
670
|
|
|
‡a
Author's Percutaneous transhepatic portal vein angioplasty and stent placement after liver transplantation: early experience.
|
|
670
|
|
|
‡a
Author's Pharmacokinetics of cyclosporine pre- and post-liver transplantation
|
|
670
|
|
|
‡a
Author's Planned Exploration of Pediatric Liver Transplant Recipients Reduces Posttransplant Morbidity and Lowers Length of Hospitalization
|
|
670
|
|
|
‡a
Author's Possible recurrence of primary sclerosing cholangitis following living-related liver transplantation: report of a case
|
|
670
|
|
|
‡a
Author's Post-operative assessment in patients after liver transplantation: imaging parameters associated with 1-year graft failure
|
|
670
|
|
|
‡a
Author's Posttransplant metabolic syndrome in children and adolescents after liver transplantation: a systematic review
|
|
670
|
|
|
‡a
Author's Posttransplantation growth in pediatric liver recipients
|
|
670
|
|
|
‡a
Author's Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation
|
|
670
|
|
|
‡a
Author's Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation
|
|
670
|
|
|
‡a
Author's Pre-Existing Melanoma and Hematological Malignancies, Prognosis and Timing to Solid Organ Transplantation: A Consensus Expert Opinion Statement
|
|
670
|
|
|
‡a
Author's Pre-Transplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement
|
|
670
|
|
|
‡a
Author's Predicting biliary complications in right lobe liver transplant recipients according to distance between donor's bile duct and corresponding hepatic artery
|
|
670
|
|
|
‡a
Author's Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points.
|
|
670
|
|
|
‡a
Author's Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease.
|
|
670
|
|
|
‡a
Author's Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores
|
|
670
|
|
|
‡a
Author's Predictors associated with terminal renal function in deceased organ donors in the intensive care unit
|
|
670
|
|
|
‡a
Author's Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation
|
|
670
|
|
|
‡a
Author's Predictors of the cost of liver transplantation
|
|
670
|
|
|
‡a
Author's Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma
|
|
670
|
|
|
‡a
Author's Preoperative Autologous Blood Collection in Adult Living Liver Donors: Are We Wasting Donor Blood and Increasing Exposure to Risk?
|
|
670
|
|
|
‡a
Author's Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality
|
|
670
|
|
|
‡a
Author's Prioritization of patients with liver cancer within the MELD system
|
|
670
|
|
|
‡a
Author's Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Prolonged cold ischemia time obviates the benefits of 0 HLA mismatches in renal transplantation
|
|
670
|
|
|
‡a
Author's Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
|
|
670
|
|
|
‡a
Author's Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve
|
|
670
|
|
|
‡a
Author's Pulmonary hypertension associated with liver disease is not reversible after liver transplantation
|
|
670
|
|
|
‡a
Author's Quantifying the risk of incompatible kidney transplantation: a multicenter study.
|
|
670
|
|
|
‡a
Author's Race/ethnicity is associated with ABO-nonidentical liver transplantation in the United States
|
|
670
|
|
|
‡a
Author's Rapid infusion technique as a safe alternative to veno-venous bypass in orthotopic liver transplant
|
|
670
|
|
|
‡a
Author's Rapid infusion technique as a safe alternative to veno-venous bypass in orthotopic liver transplant (TX).
|
|
670
|
|
|
‡a
Author's Recurrent and acquired hepatitis C viral infection in liver transplant recipients
|
|
670
|
|
|
‡a
Author's Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis
|
|
670
|
|
|
‡a
Author's Reducing the Shortage of Transplant Kidneys: A Lost Opportunity for the US Health Resources and Services Administration (HRSA)
|
|
670
|
|
|
‡a
Author's Removing Disincentives to Kidney Donation: A Quantitative Analysis
|
|
670
|
|
|
‡a
Author's Reply (to LTE HEP-17-2332).
|
|
670
|
|
|
‡a
Author's Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States
|
|
670
|
|
|
‡a
Author's Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor
|
|
670
|
|
|
‡a
Author's Response to clinical assessments of health status as a potential marker to identify patients who are too sick to undergo transplantation
|
|
670
|
|
|
‡a
Author's Response to letter to the editors
|
|
670
|
|
|
‡a
Author's Retransplantation After Living Donor Liver Transplantation: Data from the Adult to Adult Living Donor Liver Transplantation Study (A2ALL)
|
|
670
|
|
|
‡a
Author's Reversal of chronic rejection after treatment failure with FK506 and RS61443
|
|
670
|
|
|
‡a
Author's Rex shunt preoperative imaging: diagnostic capability of imaging modalities
|
|
670
|
|
|
‡a
Author's Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Risks associated with conversion of stable patients after liver transplantation to the microemulsion formulation of cyclosporine
|
|
670
|
|
|
‡a
Author's Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation
|
|
670
|
|
|
‡a
Author's Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results
|
|
670
|
|
|
‡a
Author's Serum sodium predicts mortality in patients listed for liver transplantation
|
|
670
|
|
|
‡a
Author's Setting rules for the sandbox: A response to "Successfully sharing the sandbox: A perspective on combined DCD liver and heart donor procurement"
|
|
670
|
|
|
‡a
Author's Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia
|
|
670
|
|
|
‡a
Author's Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients
|
|
670
|
|
|
‡a
Author's Should Patients With NAFLD/NASH Be Surveyed for HCC?
|
|
670
|
|
|
‡a
Author's Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient
|
|
670
|
|
|
‡a
Author's SIR 2006 Annual Meeting Film Panel Case: Budd-Chiari syndrome in a patient with Cogan syndrome.
|
|
670
|
|
|
‡a
Author's Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation
|
|
670
|
|
|
‡a
Author's Small bowel motility following major intra-abdominal surgery: the effects of opiates and rectal cisapride
|
|
670
|
|
|
‡a
Author's Solving the organ shortage crisis: the 7th annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium
|
|
670
|
|
|
‡a
Author's Split Liver Transplantation and Pediatric Waitlist Mortality in the United States: Potential for Improvement
|
|
670
|
|
|
‡a
Author's Split liver transplantation is utilized infrequently and concentrated at few transplant centers in the United States
|
|
670
|
|
|
‡a
Author's Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity
|
|
670
|
|
|
‡a
Author's Stimulus for organ donation: a survey of the American Society of Transplant Surgeons membership
|
|
670
|
|
|
‡a
Author's Strategies for tolerance induction: potential applications in living donor liver transplantation
|
|
670
|
|
|
‡a
Author's Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA.
|
|
670
|
|
|
‡a
Author's Superselective arterial embolization in the liver transplant recipient: a safe treatment for hemobilia caused by percutaneous transhepatic biliary drainage
|
|
670
|
|
|
‡a
Author's Surgical anatomy of the left lateral segment as applied to living-donor and split-liver transplantation: a clinicopathologic study
|
|
670
|
|
|
‡a
Author's Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.
|
|
670
|
|
|
‡a
Author's T-cell receptor-V alpha gene use in sequential liver allograft biopsies.
|
|
670
|
|
|
‡a
Author's Targeted gene therapy with CD40Ig to induce long-term acceptance of liver allografts.
|
|
670
|
|
|
‡a
Author's The Authors' Reply
|
|
670
|
|
|
‡a
Author's The Authors' Reply: Biliary Bicarbonate, pH, and Glucose Are Suitable Biomarkers of Biliary Viability During Ex Situ Normothermic Machine Perfusion of Human Donor Livers
|
|
670
|
|
|
‡a
Author's The cost of procuring deceased donor kidneys: Evidence from OPO cost reports 2013-2017
|
|
670
|
|
|
‡a
Author's The Declaration of Istanbul: review and commentary by the American Society of Transplant Surgeons Ethics Committee and Executive Committee.
|
|
670
|
|
|
‡a
Author's The Evolution of Organ Allocation for Liver Transplantation: Tackling Geographic Disparity Through Broader Sharing.
|
|
670
|
|
|
‡a
Author's The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's The impact of surgical complications after liver transplantation on resource utilization
|
|
670
|
|
|
‡a
Author's The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome
|
|
670
|
|
|
‡a
Author's The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis
|
|
670
|
|
|
‡a
Author's The influence of portoenterostomy on transplantation for biliary atresia.
|
|
670
|
|
|
‡a
Author's The management of T tube leaks in orthotopic liver transplant recipients with endoscopically placed nasobiliary catheters.
|
|
670
|
|
|
‡a
Author's The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation
|
|
670
|
|
|
‡a
Author's The report of a national conference on the wait list for kidney transplantation
|
|
670
|
|
|
‡a
Author's The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors.
|
|
670
|
|
|
‡a
Author's The use of a micro-bubble contrast agent to allow visualization of the biliary tree
|
|
670
|
|
|
‡a
Author's The use of stents for duct-to-duct anastomoses of biliary reconstruction in orthotopic liver transplantation.
|
|
670
|
|
|
‡a
Author's The use of the T tube after orthotopic liver transplantation
|
|
670
|
|
|
‡a
Author's Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function
|
|
670
|
|
|
‡a
Author's Time course of cyclosporine and ist motabolites in blood, liver and spleen of naive Lewis rats: comparison with preliminary data obtained in transplanted animals
|
|
670
|
|
|
‡a
Author's Total Vascular Exclusion for Major Hepatectomy in Patients With Abnormal Liver Parenchyma
|
|
670
|
|
|
‡a
Author's Transjugular intrahepatic portosystemic shunts: preliminary results in 25 patients
|
|
670
|
|
|
‡a
Author's Transplant center regulations--a mixed blessing? An ASTS Council viewpoint
|
|
670
|
|
|
‡a
Author's Transplant renal artery stenosis
|
|
670
|
|
|
‡a
Author's Transplant surgery fellow perceptions about training and the ensuing job market-are the right number of surgeons being trained?
|
|
670
|
|
|
‡a
Author's Transplant tourism and unregulated black-market trafficking of organs
|
|
670
|
|
|
‡a
Author's Transplant tourism to China: the impact on domestic patient-care decisions
|
|
670
|
|
|
‡a
Author's Transplantation: Allocation of liver transplants-a road to consensus
|
|
670
|
|
|
‡a
Author's Transplanting kidneys without points for HLA-B matching: consequences of the policy change
|
|
670
|
|
|
‡a
Author's Transporting live donor kidneys for kidney paired donation: initial national results.
|
|
670
|
|
|
‡a
Author's Treatment of Immunocompromised COVID-19 patients with Convalescent Plasma
|
|
670
|
|
|
‡a
Author's Trends over a decade of pediatric liver transplantation in the United States
|
|
670
|
|
|
‡a
Author's Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation
|
|
670
|
|
|
‡a
Author's Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients.
|
|
670
|
|
|
‡a
Author's Use of a hepatitis C virus
|
|
670
|
|
|
‡a
Author's Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient
|
|
670
|
|
|
‡a
Author's Use of CT cholangiography to evaluate the biliary tract after liver transplantation: initial experience
|
|
670
|
|
|
‡a
Author's Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation
|
|
670
|
|
|
‡a
Author's Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
|
|
670
|
|
|
‡a
Author's Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation
|
|
670
|
|
|
‡a
Author's Utilization of Deceased Donor Kidneys to Initiate Living Donor Chains
|
|
670
|
|
|
‡a
Author's Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant
|
|
670
|
|
|
‡a
Author's Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database
|
|
670
|
|
|
‡a
Author's Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
|
|
670
|
|
|
‡a
Author's Warm ischemia-induced alterations in oxidative and inflammatory proteins in hepatic Kupffer cells in rats
|
|
670
|
|
|
‡a
Author's We Need to Take the Next Step.
|
|
670
|
|
|
‡a
Author's Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list
|
|
670
|
|
|
‡a
Author's Would government compensation of living kidney donors exploit the poor? An empirical analysis
|
|
909
|
|
|
‡a
(orcid) 0000000333039406
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessofdirectactingantiviraltreatmentinhepatitis100infectedlivertransplantcandidateswithcompensatedcirrhosisandhepatocellularcarcinoma
‡A
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma
‡9
1
|
|
919
|
|
|
‡a
contemporarymanagementofhepaticcystdiseasetechniquesandoutcomesatatertiaryhepatobiliarycenter
‡A
Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center
‡9
1
|
|
919
|
|
|
‡a
consumeristresponsestoscarcityoforgansfortransplant
‡A
Consumerist responses to scarcity of organs for transplant
‡9
1
|
|
919
|
|
|
‡a
consensusbasedperioperativeprotocolsduringthecovid19pandemic
‡A
Consensus-based perioperative protocols during the COVID-19 pandemic
‡9
1
|
|
919
|
|
|
‡a
concordanceof2orderportalvenousandbiliarytractanatomiesonmdctangiographyandmdctcholangiography
‡A
Concordance of second-order portal venous and biliary tract anatomies on MDCT angiography and MDCT cholangiography
‡9
1
|
|
919
|
|
|
‡a
completeimmunosuppressionwithdrawalandsubsequentallograftfunctionamongpediatricrecipientsofparentallivingdonorlivertransplants
‡A
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants
‡9
1
|
|
919
|
|
|
‡a
comparisonof3regimensforcytomegalovirusprophylaxisin147livertransplantrecipients
‡A
Comparison of three regimens for cytomegalovirus prophylaxis in 147 liver transplant recipients.
‡9
1
|
|
919
|
|
|
‡a
comparisonofoutcomesafterdelayedgraftfunctionsirolimusbasedversusothercalcineurininhibitorsparinginductionimmunosuppressionregimens
‡A
Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens
‡9
1
|
|
919
|
|
|
‡a
comparisonofbiliarycomplicationsinadultlivingdonorlivertransplantsperformedat2busytransplantcenters
‡A
Comparison of biliary complications in adult living-donor liver transplants performed at two busy transplant centers
‡9
1
|
|
919
|
|
|
‡a
clinicianassessmentsofhealthstatuspredictmortalityinpatientswithendstageliverdiseaseawaitinglivertransplantation
‡A
Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation
‡9
1
|
|
919
|
|
|
‡a
cladosporiumtrichoidescerebralphaeohyphomycosisinalivertransplantrecipientreportofacase
‡A
Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case
‡9
1
|
|
919
|
|
|
‡a
characterizationofdistalcolonicmotilityinearlypostoperativeperiodandeffectofcolonicanastomosis
‡A
Characterization of distal colonic motility in early postoperative period and effect of colonic anastomosis
‡9
1
|
|
919
|
|
|
‡a
characterizationofacyclosporinecontainingliposome
‡A
Characterization of a cyclosporine-containing liposome
‡9
1
|
|
919
|
|
|
‡a
chaintransplantationinitialexperienceofalargemulticenterprogram
‡A
Chain transplantation: initial experience of a large multicenter program
‡9
1
|
|
919
|
|
|
‡a
centralvenouspressuremonitoringduringlivingrightdonorhepatectomy
‡A
Central venous pressure monitoring during living right donor hepatectomy
‡9
1
|
|
919
|
|
|
‡a
centerlevelvariationinhlaincompatiblelivingdonorkidneytransplantationoutcomes
‡A
Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes
‡9
1
|
|
919
|
|
|
‡a
cd69expressiononperipheralcd8tcellscorrelateswithacuterejectioninrenaltransplantrecipients
‡A
CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients
‡9
1
|
|
919
|
|
|
‡a
calcineurininhibitorfreemycophenolatemofetilsirolimusmaintenanceinlivertransplantationtherandomizedsparethenephrontrial
‡A
Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial
‡9
1
|
|
919
|
|
|
‡a
biliarytractdepictioninlivingpotentialliverdonorscomparisonofconventionalmrmangafodipirtrisodiumenhancedexcretorymrandmultidetectorrowctcholangiographyinitialexperience
‡A
Biliary tract depiction in living potential liver donors: comparison of conventional MR, mangafodipir trisodium-enhanced excretory MR, and multi-detector row CT cholangiography--initial experience
‡9
1
|
|
919
|
|
|
‡a
biliarycomplicationsofreducedorganlivertransplantation
‡A
Biliary complications of reduced-organ liver transplantation
‡9
1
|
|
919
|
|
|
‡a
biliarycomplicationsfollowinglivingdonorhepatectomy
‡A
Biliary complications following living donor hepatectomy
‡9
1
|
|
919
|
|
|
‡a
biliarycomplicationsafterlivertransplantationinchildren
‡A
Biliary complications after liver transplantation in children
‡9
1
|
|
919
|
|
|
‡a
biasesinthereportingofhepatocellularcarcinomatumorsizesonthelivertransplantwaitinglist
‡A
Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list
‡9
1
|
|
919
|
|
|
‡a
biorganpairedexchangesentinelcaseofaliverkidneyswap
‡A
Bi-organ paired exchange-Sentinel case of a liver-kidney swap
‡9
1
|
|
919
|
|
|
‡a
auxiliarylivertransplantinfulminantfailure
‡A
Auxiliary Liver Transplant in Fulminant Failure
‡9
1
|
|
919
|
|
|
‡a
authorresponsereducinginfectiontransmissioninsolidorgantransplantationthroughdonornucleicacidtestingacosteffectivenessanalysis
‡A
Author response: reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis
‡9
1
|
|
919
|
|
|
‡a
astsrecommendedpracticeguidelinesforcontrolleddonationaftercardiacdeathorganprocurementandtransplantation
‡A
ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation
‡9
1
|
|
919
|
|
|
‡a
arethereupperlimitsintumorburdenfordownstagingofhepatocellularcarcinomatolivertransplantanalysisoftheallcomersprotocol
‡A
Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol
‡9
1
|
|
919
|
|
|
‡a
applyingexpandedcriteriatolivertransplantationforhepatocellularcarcinomatoomuchtoosoonorisnowthetime
‡A
Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?
‡9
1
|
|
919
|
|
|
‡a
applicabilitytolerabilityandefficacyofpreemptiveantiviraltherapyinhepatitis100infectedpatientsundergoinglivertransplantation
‡A
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.
‡9
1
|
|
919
|
|
|
‡a
antibodytothehostcellulargenederivedepitopegor1inlivertransplantrecipientswithhepatitis100virusinfection
‡A
Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection.
‡9
1
|
|
919
|
|
|
‡a
anestheticcareofpatientswithcriglernajjarsyndrome
‡A
Anesthetic Care of Patients With Crigler-Najjar Syndrome
‡9
1
|
|
919
|
|
|
‡a
anastomosinghemangiomaofliver
‡A
Anastomosing hemangioma of liver
‡9
1
|
|
919
|
|
|
‡a
olderliverinthehandorapossiblyyoungerliverinthebush
‡A
An older liver in the hand, or a (possibly) younger liver in the bush?
‡9
1
|
|
919
|
|
|
‡a
eyetoquality
‡A
An eye to quality
‡9
1
|
|
919
|
|
|
‡a
americansocietyoftransplantsurgeonstransplantcenteroutcomesrequirementsathreattoinnovation
‡A
American Society of Transplant Surgeons transplant center outcomes requirements--a threat to innovation
‡9
1
|
|
919
|
|
|
‡a
alphafetoproteinslope75ng1050permonthpredictsmicrovascularinvasionandtumorrecurrenceafterlivertransplantationforhepatocellularcarcinoma
‡A
Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma
‡9
1
|
|
919
|
|
|
‡a
alphafetoproteinlevel1000ng1050asanexclusioncriterionforlivertransplantationinpatientswithhepatocellularcarcinomameetingthemilancriteria
‡A
Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria
‡9
1
|
|
919
|
|
|
‡a
alphafetoproteindecreasefrom1000to500ng1050inpatientswithhepatocellularcarcinomaleadstoimprovedposttransplantoutcomes
‡A
Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes
‡9
1
|
|
919
|
|
|
‡a
allograftrejectioninpediatriclivertransplantationcomparisonbetweencadavericandlivingrelateddonors
‡A
Allograft rejection in pediatric liver transplantation: Comparison between cadaveric and living related donors
‡9
1
|
|
919
|
|
|
‡a
adultlivingdonorliverimaging
‡A
Adult living donor liver imaging
‡9
1
|
|
919
|
|
|
‡a
acutelivertransplantationrejectionearlydetectionofendothelialleakinaratmodelusingmagneticresonanceimagingandamacromolecularcontrastmedium
‡A
Acute liver transplantation rejection. Early detection of endothelial leak in a rat model using magnetic resonance imaging and a macromolecular contrast medium.
‡9
1
|
|
919
|
|
|
‡a
acutekidneyinjuryduringlivertransplantationasdeterminedbyneutrophilgelatinaseassociatedlipocalin
‡A
Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin
‡9
1
|
|
919
|
|
|
‡a
accuracyofplainabdominalradiographsinthedetectionofretainedsurgicalneedlesintheperitonealcavity
‡A
Accuracy of plain abdominal radiographs in the detection of retained surgical needles in the peritoneal cavity
‡9
1
|
|
919
|
|
|
‡a
accuracyofdopplerestimatedpulmonaryvascularresistanceinpatientsbeforelivertransplantation
‡A
Accuracy of Doppler-estimated pulmonary vascular resistance in patients before liver transplantation
‡9
1
|
|
919
|
|
|
‡a
abononidenticallivertransplantationintheunitedstates
‡A
ABO-Nonidentical Liver Transplantation in the United States
‡9
1
|
|
919
|
|
|
‡a
a2livertransplantationacrosstheabobarrierincreasingoptionsinthedonorpool
‡A
A2 liver transplantation across the ABO barrier: Increasing options in the donor pool?
‡9
1
|
|
919
|
|
|
‡a
virtualcrossmatchbasedstrategyfacilitatessharingofdeceaseddonorkidneysforhighlysensitizedrecipients
‡A
A virtual crossmatch based strategy facilitates sharing of deceased donor kidneys for highly sensitized recipients
‡9
1
|
|
919
|
|
|
‡a
randomizedmulticenterstudycomparingsteroidfreeimmunosuppressionandstandardimmunosuppressionforlivertransplantrecipientswithchronichepatitis100
‡A
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
‡9
1
|
|
919
|
|
|
‡a
prospectivestudyondownstagingofhepatocellularcarcinomapriortolivertransplantation
‡A
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
‡9
1
|
|
919
|
|
|
‡a
novelwaitlistdropoutscoreforhepatocellularcarcinomaidentifyingathresholdthatpredictsworseposttransplantsurvival
‡A
A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival
‡9
1
|
|
919
|
|
|
‡a
modifiedvascularsleeveanastomosisforrearterializationinorthotopiclivertransplantationinrats
‡A
A modified vascular "sleeve" anastomosis for rearterialization in orthotopic liver transplantation in rats
‡9
1
|
|
919
|
|
|
‡a
formulatocalculatestandardlivervolumeusingthoracoabdominalcircumference
‡A
A Formula to Calculate Standard Liver Volume Using Thoracoabdominal Circumference.
‡9
1
|
|
919
|
|
|
‡a
followupanalysisofthepatternandpredictorsofdropoutfromthewaitinglistforlivertransplantationinpatientswithhepatocellularcarcinomaimplicationsforthecurrentorganallocationpolicy
‡A
A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy
‡9
1
|
|
919
|
|
|
‡a
calcineurininhibitorsparingregimenwithsirolimusmycophenolatemofetilandanticd25mabprovideseffectiveimmunosuppressioninkidneytransplantrecipientswithdelayedorimpairedgraftfunction
‡A
A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function
‡9
1
|
|
919
|
|
|
‡a
3dt2weightedandgdeobdtpaenhanced3dt1weightedmrcholangiographyforevaluationofbiliaryanatomyinlivingliverdonors
‡A
3D T2-weighted and Gd-EOB-DTPA-enhanced 3D T1-weighted MR cholangiography for evaluation of biliary anatomy in living liver donors
‡9
1
|
|
919
|
|
|
‡a
transportinglivedonorkidneysforkidneypaireddonationinitialnationalresults
‡A
Transporting live donor kidneys for kidney paired donation: initial national results.
‡9
1
|
|
919
|
|
|
‡a
treatmentofimmunocompromisedcovid19patientswithconvalescentplasma
‡A
Treatment of Immunocompromised COVID-19 patients with Convalescent Plasma
‡9
1
|
|
919
|
|
|
‡a
trendsoveradecadeofpediatriclivertransplantationintheunitedstates
‡A
Trends over a decade of pediatric liver transplantation in the United States
‡9
1
|
|
919
|
|
|
‡a
tumorsurveillancewhatcanandshouldbedonescreeningforrecurrenceofhepatocellularcarcinomaafterlivertransplantation
‡A
Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation
‡9
1
|
|
919
|
|
|
‡a
2yearoutcomefollowingtransjugularintrahepaticportosystemicshuntforvaricealbleedingresultsin90patients
‡A
Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients.
‡9
1
|
|
919
|
|
|
‡a
useofahepatitis100virus
‡A
Use of a hepatitis C virus
‡9
1
|
|
919
|
|
|
‡a
useofahepatitis100virushcvrnapositivedonorinatreatedhcvrnanegativelivertransplantrecipient
‡A
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient
‡9
1
|
|
919
|
|
|
‡a
useofctcholangiographytoevaluatethebiliarytractafterlivertransplantationinitialexperience
‡A
Use of CT cholangiography to evaluate the biliary tract after liver transplantation: initial experience
‡9
1
|
|
919
|
|
|
‡a
useoflivingdonorlivertransplantationvarieswiththeavailabilityofdeceaseddonorlivertransplantation
‡A
Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation
‡9
1
|
|
919
|
|
|
‡a
useofrifabutinforthetreatmentofalatenttuberculosisinfectioninapatientaftersolidorgantransplantation
‡A
Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
‡9
1
|
|
919
|
|
|
‡a
usingtransjugularintrahepaticportosystemicshuntstocontrolvaricealbleedingbeforelivertransplantation
‡A
Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation
‡9
1
|
|
919
|
|
|
‡a
utilizationofdeceaseddonorkidneystoinitiatelivingdonorchains
‡A
Utilization of Deceased Donor Kidneys to Initiate Living Donor Chains
‡9
1
|
|
919
|
|
|
‡a
validationofariskestimationoftumorrecurrenceaftertransplantretreatscoreforhepatocellularcarcinomarecurrenceafterlivertransplant
‡A
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant
‡9
1
|
|
919
|
|
|
‡a
validationoftheprognosticpoweroftheretreatscoreforhepatocellularcarcinomarecurrenceusingtheunosdatabase
‡A
Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database
‡9
1
|
|
919
|
|
|
‡a
waittimeoflessthan6andgreaterthan18monthspredictshepatocellularcarcinomarecurrenceafterlivertransplantationproposingawaittimesweetspot
‡A
Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
‡9
1
|
|
919
|
|
|
‡a
warmischemiainducedalterationsinoxidativeandinflammatoryproteinsinhepatickupffercellsinrats
‡A
Warm ischemia-induced alterations in oxidative and inflammatory proteins in hepatic Kupffer cells in rats
‡9
1
|
|
919
|
|
|
‡a
weneedtotakethenextstep
‡A
We Need to Take the Next Step.
‡9
1
|
|
919
|
|
|
‡a
weighingtherisksmorbidobesityanddiabetesareassociatedwithincreasedriskofdeathonthelivertransplantwaitinglist
‡A
Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list
‡9
1
|
|
919
|
|
|
‡a
wouldgovernmentcompensationoflivingkidneydonorsexploitthepooranempiricalanalysis
‡A
Would government compensation of living kidney donors exploit the poor? An empirical analysis
‡9
1
|
|
919
|
|
|
‡a
hepaticgranulomasfollowinglivertransplantationclinicopathologicfeaturesin42patients
‡A
Hepatic granulomas following liver transplantation. Clinicopathologic features in 42 patients.
‡9
1
|
|
919
|
|
|
‡a
hepaticsteatosisat1yearisanadditionalpredictorofsubsequentfibrosisseverityinlivertransplantrecipientswithrecurrenthepatitis100virus
‡A
Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus
‡9
1
|
|
919
|
|
|
‡a
hepatitisafterlivertransplantationtheroleoftheknownandunknownviruses
‡A
Hepatitis after liver transplantation: the role of the known and unknown viruses.
‡9
1
|
|
919
|
|
|
‡a
hepatitisbvirusquasispeciesinhepaticandextrahepaticviralreservoirsinlivertransplantrecipientsonprophylactictherapy
‡A
Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy
‡9
1
|
|
919
|
|
|
‡a
hepatitis100virusnotfoundinfulminantnonanonbhepatitis
‡A
Hepatitis C Virus Not Found in Fulminant Non-A, Non-B Hepatitis
‡9
1
|
|
919
|
|
|
‡a
hepatitisgvirusinpatientswithcryptogenicliverdiseaseundergoinglivertransplantation
‡A
Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantation
‡9
1
|
|
919
|
|
|
‡a
hepatocellularcarcinomaablateandwaitversusrapidtransplantation
‡A
Hepatocellular carcinoma: Ablate and wait versus rapid transplantation
‡9
1
|
|
919
|
|
|
‡a
hepatotoxinsandlivertransplantationdecreasepulmonarymetastasesinratswithhepatoma
‡A
Hepatotoxins and liver transplantation decrease pulmonary metastases in rats with hepatoma
‡9
1
|
|
919
|
|
|
‡a
highincidenceofrecurrenceandhematologiceventsfollowinglivertransplantationforbuddchiarisyndrome
‡A
High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome
‡9
1
|
|
919
|
|
|
‡a
histopathologicstudyoftransjugularintrahepaticportosystemicshunts
‡A
Histopathologic study of transjugular intrahepatic portosystemic shunts
‡9
1
|
|
919
|
|
|
‡a
historyofmarijuanausedoesnotaffectoutcomesonthelivertransplantwaitlist
‡A
History of marijuana use does not affect outcomes on the liver transplant waitlist
‡9
1
|
|
919
|
|
|
‡a
hivinfectedliverandkidneytransplantrecipients1and3yearoutcomes
‡A
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes
‡9
1
|
|
919
|
|
|
‡a
hospitalreadmissionsfollowinghlaincompatiblelivedonorkidneytransplantationamulticenterstudy
‡A
Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study
‡9
1
|
|
919
|
|
|
‡a
2andil5geneexpressioninresponsetoalloantigeninliverallograftrecipientsandinvitro
‡A
IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro
‡9
1
|
|
919
|
|
|
‡a
imageofthemonthportalhypertensivebiliopathy
‡A
Image of the month. Portal hypertensive biliopathy.
‡9
1
|
|
919
|
|
|
‡a
impactofaqualityimprovementprojectondeceasedorgandonormanagement
‡A
Impact of a quality improvement project on deceased organ donor management
‡9
1
|
|
919
|
|
|
‡a
impactofgraftselectionondonorandrecipientoutcomesafterlivingdonorlivertransplantation
‡A
Impact of Graft Selection on Donor and Recipient Outcomes After Living Donor Liver Transplantation
‡9
1
|
|
919
|
|
|
‡a
impactofpreclinicalexposuretoorgandonationonknowledgeandattitudesofmedicalstudents
‡A
Impact of preclinical exposure to organ donation on knowledge and attitudes of medical students.
‡9
1
|
|
919
|
|
|
‡a
impactofthepediatricendstageliverdiseasepeldgrowthfailurethresholdsonmortalityamongpediatriclivertransplantcandidates
‡A
Impact of the Pediatric End-Stage Liver Disease (PELD) growth failure thresholds on mortality among pediatric liver transplant candidates
‡9
1
|
|
919
|
|
|
‡a
improvingliverallocationmeldandpeld
‡A
Improving liver allocation: MELD and PELD.
‡9
1
|
|
919
|
|
|
‡a
incidenceandclinicalconsequencesofsurfaceandpolymerasegenemutationsinlivertransplantrecipientsonhepatitisbimmunoglobulin
‡A
Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.
‡9
1
|
|
919
|
|
|
‡a
incidenceandsignificanceofaspergillusculturesfollowingliverandkidneytransplantation
‡A
Incidence and significance of Aspergillus cultures following liver and kidney transplantation
‡9
1
|
|
919
|
|
|
‡a
increasedefficacyofcsafollowingrearterializationintheratoltxmodel
‡A
Increased efficacy of CSA following rearterialization in the rat OLTX model
‡9
1
|
|
919
|
|
|
‡a
increasedhepatocellularcarcinomarecurrenceinwomencomparedtomenwithhighalphafetoproteinatlivertransplant
‡A
Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant
‡9
1
|
|
919
|
|
|
‡a
increasedseverityofrenalischemiareperfusioninjurywithvenousclampingcomparedtoarterialclampinginaratmodel
‡A
Increased severity of renal ischemia-reperfusion injury with venous clamping compared to arterial clamping in a rat model
‡9
1
|
|
919
|
|
|
‡a
increasinglivertransplantationwaitlistdropoutforhepatocellularcarcinomawithwideninggeographicaldisparitiesimplicationsfororganallocation
‡A
Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
‡9
1
|
|
919
|
|
|
‡a
influenceofgrafttypeonoutcomesafterpediatriclivertransplantation
‡A
Influence of graft type on outcomes after pediatric liver transplantation
‡9
1
|
|
919
|
|
|
‡a
intentiontotreatoutcomeoft1hepatocellularcarcinomawiththewaitandnotablateapproachuntilmeetingt2criteriaforlivertransplantlisting
‡A
Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing
‡9
1
|
|
919
|
|
|
‡a
interferonalfaforrecurrenthepatitisbinfectionafterlivertransplantation
‡A
Interferon alfa for recurrent hepatitis B infection after liver transplantation
‡9
1
|
|
919
|
|
|
‡a
internationallivertransplantationsocietyconsensusstatementonimmunosuppressioninlivertransplantrecipients
‡A
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients
‡9
1
|
|
919
|
|
|
‡a
intracranialpressuremonitoringandlivertransplantationforfulminanthepaticfailure
‡A
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure
‡9
1
|
|
919
|
|
|
‡a
intragraftcytokineprofileduringhumanliverallograftrejection
‡A
Intragraft cytokine profile during human liver allograft rejection
‡9
1
|
|
919
|
|
|
‡a
intragrafteosinophiliaandinterleukin5mrnaaccompanyliverallograftrejection
‡A
Intragraft eosinophilia and interleukin-5 mRNA accompany liver allograft rejection.
‡9
1
|
|
919
|
|
|
‡a
intrahepaticportocavalshuntforvaricealhemorrhagepriortolivertransplantation
‡A
Intrahepatic portocaval shunt for variceal hemorrhage prior to liver transplantation.
‡9
1
|
|
919
|
|
|
‡a
intramuscularhepatitisbimmuneglobulincombinedwithlamivudineforprophylaxisagainsthepatitisbrecurrenceafterlivertransplantation
‡A
Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
‡9
1
|
|
919
|
|
|
‡a
intraoperativehemodynamicsandliverfunctioninadulttoadultlivingliverdonors
‡A
Intraoperative hemodynamics and liver function in adult-to-adult living liver donors
‡9
1
|
|
919
|
|
|
‡a
ischemiareperfusioninjuryismoresevereinolderversusyoungratlivers
‡A
Ischemia-reperfusion injury is more severe in older versus young rat livers.
‡9
1
|
|
919
|
|
|
‡a
ischemicpreconditioningimprovesenergystateandtransplantationsurvivalinobesezuckerratlivers
‡A
Ischemic preconditioning improves energy state and transplantation survival in obese Zucker rat livers
‡9
1
|
|
919
|
|
|
‡a
isolationoffunctionalmhcclass1deficientisletcells
‡A
Isolation of functional MHC class I-deficient islet cells.
‡9
1
|
|
919
|
|
|
‡a
justifyingnonstandardexceptionrequestsforpediatriclivertransplantcandidatesananalysisofnarrativessubmittedtotheunitednetworkfororgansharing2009
‡A
Justifying Nonstandard Exception Requests for Pediatric Liver Transplant Candidates: An Analysis of Narratives Submitted to the United Network for Organ Sharing, 2009-2014.
‡9
1
|
|
919
|
|
|
‡a
kidneyandlivertransplantationinhumanimmunodeficiencyvirusinfectedpatientsapilotsafetyandefficacystudy
‡A
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study
‡9
1
|
|
919
|
|
|
‡a
lackofbenefitsofmammaliantargetofrapamycininhibitorinpatientstransplantedforhepatocellularcarcinomaisthistheendofthestory
‡A
Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
‡9
1
|
|
919
|
|
|
‡a
laparoscopicprocurementofkidneyswithmultiplerenalarteriesisassociatedwithincreasedureteralcomplicationsintherecipient
‡A
Laparoscopic procurement of kidneys with multiple renal arteries is associated with increased ureteral complications in the recipient
‡9
1
|
|
919
|
|
|
‡a
laparoscopicrightdonornephrectomyalargesinglecenterexperience
‡A
Laparoscopic right donor nephrectomy: a large single-center experience
‡9
1
|
|
919
|
|
|
‡a
leftlobeadulttoadultlivingdonorlivertransplantationsmallgraftsandhemiportocavalshuntsinthepreventionofsmallforsizesyndrome
‡A
Left lobe adult-to-adult living donor liver transplantation: small grafts and hemiportocaval shunts in the prevention of small-for-size syndrome
‡9
1
|
|
919
|
|
|
‡a
livedonorlivertransplantationintheunitedstatesimpactofshare35onlivedonorutilization
‡A
Live Donor Liver Transplantation in the United States: Impact of Share 35 on Live Donor Utilization
‡9
1
|
|
919
|
|
|
‡a
liverallocationanddistributionpossiblenextsteps
‡A
Liver allocation and distribution: possible next steps.
‡9
1
|
|
919
|
|
|
‡a
liverandintestinetransplantation
‡A
Liver and intestine transplantation
‡9
1
|
|
919
|
|
|
‡a
livertransplantationattheuniversityofcalifornia3francisco
‡A
Liver transplantation at the University of California, San Francisco
‡9
1
|
|
919
|
|
|
‡a
livertransplantationatucsfa20yearexperience
‡A
Liver transplantation at UCSF--a 20-year experience.
‡9
1
|
|
919
|
|
|
‡a
livertransplantationcomplicatedbymalpositionedtransjugularintrahepaticportosystemicshunts
‡A
Liver transplantation complicated by malpositioned transjugular intrahepatic portosystemic shunts.
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforautoimmunehepatitisrejectionandrecurrence
‡A
Liver transplantation for autoimmune hepatitis: rejection and recurrence
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforfulminanthepaticfailure
‡A
Liver transplantation for fulminant hepatic failure
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomaanalysisoffactorspredictingoutcomein1074patientsinoptnregion5
‡A
Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomaanalysisofsurvivalaccordingtotheintentiontotreatprincipleanddropoutfromthewaitinglist
‡A
Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomacomparisonoftheproposeducsfcriteriawiththemilancriteriaandthepittsburghmodifiedtnmcriteria
‡A
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomaexpansionofthetumorsizelimitsdoesnotadverselyimpactsurvival
‡A
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomalessonsfromthe1yearunderthemodelofendstageliverdisease
‡A
Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomalessonsfromthe1yearunderthemodelofendstageliverdiseasemeldorganallocationpolicy
‡A
Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomaresultswithpreoperativechemoembolization
‡A
Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization.
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomavalidationoftheucsfexpandedcriteriabasedonpreoperativeimaging
‡A
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforhepatocellularcarcinomaworkinggroupreportfromtheiltstransplantoncologyconsensusconference
‡A
Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforsclerosingcholangitis
‡A
Liver transplantation for sclerosing cholangitis
‡9
1
|
|
919
|
|
|
‡a
livertransplantationforsevereamanitaphalloidesmushroompoisoning
‡A
Liver transplantation for severe Amanita phalloides mushroom poisoning
‡9
1
|
|
919
|
|
|
‡a
livertransplantationimprovessurvivalofratsbearinghepatoma
‡A
Liver transplantation improves survival of rats bearing hepatoma-3924A.
‡9
1
|
|
919
|
|
|
‡a
livertransplantationrecipientswithnonalcoholicsteatohepatitishavelowerriskhepatocellularcarcinoma
‡A
Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma
‡9
1
|
|
919
|
|
|
‡a
livertransplantationtoday
‡A
Liver transplantation today
‡9
1
|
|
919
|
|
|
‡a
livingdonorcandidatesforrighthepaticlobetransplantationevaluationatctcholangiographyinitialexperience
‡A
Living donor candidates for right hepatic lobe transplantation: evaluation at CT cholangiography--initial experience
‡9
1
|
|
919
|
|
|
‡a
livingdonorlivertransplantforalcoholicliverdiseasedatafromtheadulttoadultlivingdonorlivertransplantationstudy
‡A
Living Donor Liver Transplant for Alcoholic Liver Disease: Data from the Adult-to-adult Living Donor Liver Transplantation Study
‡9
1
|
|
919
|
|
|
‡a
livingkidneydonorfollowupstateoftheartandfuturedirectionsconferencesummaryandrecommendations
‡A
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations
‡9
1
|
|
919
|
|
|
‡a
livingrelateddonorlivertransplantationtheucsfexperience
‡A
Living related donor liver transplantation: the UCSF experience
‡9
1
|
|
919
|
|
|
‡a
longtermcomplicationsoflivingdonorlivertransplantation
‡A
Long-term complications of living donor liver transplantation
‡9
1
|
|
919
|
|
|
‡a
longtermhistologicaleffectsofpreemptiveantiviraltherapyinlivertransplantrecipientswithhepatitis100virusinfection
‡A
Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection
‡9
1
|
|
919
|
|
|
‡a
longtermoutcomeofhumanleukocyteantigenmismatchinginlivertransplantationresultsofthenationalinstituteofdiabetesanddigestiveandkidneydiseaseslivertransplantationdatabase
‡A
Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database
‡9
1
|
|
919
|
|
|
‡a
longtermrenalfunctionandcardiovasculardiseaseriskinobesekidneydonors
‡A
Long-term renal function and cardiovascular disease risk in obese kidney donors
‡9
1
|
|
919
|
|
|
‡a
maintenanceimmunosuppressionafterlivertransplantation
‡A
Maintenance immunosuppression after liver transplantation
‡9
1
|
|
919
|
|
|
‡a
maintenanceimmunosuppressionwithprednisoneandrs61443alonefollowinglivertransplantation
‡A
Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation.
‡9
1
|
|
919
|
|
|
‡a
majorhistocompatibilitycomplexclass1deficiencyprolongsisletallograftsurvival
‡A
Major histocompatibility complex class I deficiency prolongs islet allograft survival.
‡9
1
|
|
919
|
|
|
‡a
managementofhepatitis100infectedlivertransplantrecipientsatlargenorthamericancentreschangesinrecentyears
‡A
Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years
‡9
1
|
|
919
|
|
|
‡a
managingfinancesofshippinglivingdonorkidneysfordonorexchanges
‡A
Managing finances of shipping living donor kidneys for donor exchanges
‡9
1
|
|
919
|
|
|
‡a
massivevenousairembolismduringorthotopiclivertransplantation
‡A
Massive venous air embolism during orthotopic liver transplantation
‡9
1
|
|
919
|
|
|
‡a
metabolicprofilingofliversandbloodfromobesezuckerrats
‡A
Metabolic profiling of livers and blood from obese Zucker rats
‡9
1
|
|
919
|
|
|
‡a
mhcexpressiononhumanhepatocytesbeforeandafterisolation
‡A
MHC expression on human hepatocytes before and after isolation
‡9
1
|
|
919
|
|
|
‡a
mildhypothermiaprotectsobeseratsfromfulminanthepaticnecrosisinducedbyischemiareperfusion
‡A
Mild hypothermia protects obese rats from fulminant hepatic necrosis induced by ischemia-reperfusion.
‡9
1
|
|
919
|
|
|
‡a
mildhypothermiaprovidessignificantprotectionagainstischemiareperfusioninjuryinliversofobeseandleanrats
‡A
Mild hypothermia provides significant protection against ischemia/reperfusion injury in livers of obese and lean rats
‡9
1
|
|
919
|
|
|
‡a
minimaltransplantsurvivalbenefitforhepatocellularcarcinomaisitrealoranoverestimationofwaitlistlifeexpectancy
‡A
Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
‡9
1
|
|
919
|
|
|
‡a
misdiagnosisofhepatocellularcarcinomainpatientsreceivingnolocalregionaltherapypriortolivertransplantananalysisoftheorganprocurementandtransplantationnetworkexplantpathologyform
‡A
Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
‡9
1
|
|
919
|
|
|
‡a
mixedhepatocellularcholangiocarcinomaandintrahepaticcholangiocarcinomainpatientsundergoingtransplantationforhepatocellularcarcinoma
‡A
Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma
‡9
1
|
|
919
|
|
|
‡a
movingkidneyallocationforwardtheastsperspective
‡A
Moving kidney allocation forward: the ASTS perspective
‡9
1
|
|
919
|
|
|
‡a
multidisciplinarymanagementofhepatocellularcarcinoma
‡A
Multidisciplinary management of hepatocellular carcinoma
‡9
1
|
|
919
|
|
|
‡a
multiplelistingsasareflectionofgeographicdisparityinlivertransplantation
‡A
Multiple listings as a reflection of geographic disparity in liver transplantation
‡9
1
|
|
919
|
|
|
‡a
multivesselcoronaryarterydiseasepredictsmortalitylengthofstayandpressorrequirementsafterlivertransplantation
‡A
Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation.
‡9
1
|
|
919
|
|
|
‡a
mycophenolatemofetilmicroemulsioncyclosporineandprednisoneasprimaryimmunosuppressionforpediatriclivertransplantrecipients
‡A
Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients
‡9
1
|
|
919
|
|
|
‡a
newonsetdiabetesmellitusafterlivertransplantationthecriticalroleofhepatitis100infection
‡A
New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection.
‡9
1
|
|
919
|
|
|
‡a
noninvasiveestimationofpulmonaryvascularresistanceimprovesportopulmonaryhypertensionscreeninginlivertransplantcandidates
‡A
Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates
‡9
1
|
|
919
|
|
|
‡a
nonoperativemanagementofbiliaryleaksafterorthotopiclivertransplantation
‡A
Nonoperative management of biliary leaks after orthotopic liver transplantation
‡9
1
|
|
919
|
|
|
‡a
nonstandardexceptionrequestsimpactoutcomesforpediatriclivertransplantcandidates
‡A
Nonstandard Exception Requests Impact Outcomes for Pediatric Liver Transplant Candidates
‡9
1
|
|
919
|
|
|
‡a
occulthepatitisbvirusassourceofinfectioninlivertransplantrecipients
‡A
"Occult" hepatitis B virus as source of infection in liver transplant recipients
‡9
1
|
|
919
|
|
|
‡a
offerpatternsofnationallyplacedliversbydonationservicearea
‡A
Offer patterns of nationally placed livers by donation service area
‡9
1
|
|
919
|
|
|
‡a
opioidusepriortolivertransplantisassociatedwithincreasedriskofdeathaftertransplant
‡A
Opioid use prior to liver transplant is associated with increased risk of death after transplant
‡9
1
|
|
919
|
|
|
‡a
oraldtpascintigraphicassessmentofcolonictransitinconstipatedsubjects
‡A
Oral [111In]DTPA scintigraphic assessment of colonic transit in constipated subjects.
‡9
1
|
|
919
|
|
|
‡a
organdonationaftercardiacdeathinamyotrophiclateralsclerosis
‡A
Organ donation after cardiac death in amyotrophic lateral sclerosis
‡9
1
|
|
919
|
|
|
‡a
orthotopiclivertransplantationforendstagealcoholicliverdisease
‡A
Orthotopic liver transplantation for end-stage alcoholic liver disease.
‡9
1
|
|
919
|
|
|
‡a
outcomesforlivertransplantcandidateslistedwithlowmodelforendstageliverdiseasescore
‡A
Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
‡9
1
|
|
919
|
|
|
‡a
outcomesofsurgicalrepairofbileleaksandstricturesafteradulttoadultlivingdonorlivertransplant
‡A
Outcomes of surgical repair of bile leaks and strictures after adult-to-adult living donor liver transplant
‡9
1
|
|
919
|
|
|
‡a
outcomeswithsplitlivertransplantationin106recipientstheuniversityofcalifornia3franciscoexperiencefrom1993to
‡A
Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010.
‡9
1
|
|
919
|
|
|
‡a
overdilationofa62000selfexpandingstentwitha102000balloonexpandablestentgraftpreservesfailingmesorexbypass
‡A
Overdilation of a 6-mm Self-Expanding Stent with a 10-mm Balloon-Expandable Stent Graft Preserves Failing Meso-Rex Bypass
‡9
1
|
|
919
|
|
|
‡a
patientcenterandgeographiccharacteristicsofnationallyplacedlivers
‡A
Patient, center and geographic characteristics of nationally placed livers
‡9
1
|
|
919
|
|
|
‡a
patternsofearlyallograftdysfunctioninadultlivedonorlivertransplantationthea2allexperience
‡A
Patterns of Early Allograft Dysfunction in Adult Live Donor Liver Transplantation: The A2ALL Experience.
‡9
1
|
|
919
|
|
|
‡a
percutaneoussalvageofafailingrexshunt
‡A
Percutaneous salvage of a failing rex shunt
‡9
1
|
|
919
|
|
|
‡a
percutaneoustranshepaticportalveinangioplastyandstentplacementafterlivertransplantationearlyexperience
‡A
Percutaneous transhepatic portal vein angioplasty and stent placement after liver transplantation: early experience.
‡9
1
|
|
919
|
|
|
‡a
pharmacokineticsofcyclosporinepreandpostlivertransplantation
‡A
Pharmacokinetics of cyclosporine pre- and post-liver transplantation
‡9
1
|
|
919
|
|
|
‡a
plannedexplorationofpediatriclivertransplantrecipientsreducesposttransplantmorbidityandlowerslengthofhospitalization
‡A
Planned Exploration of Pediatric Liver Transplant Recipients Reduces Posttransplant Morbidity and Lowers Length of Hospitalization
‡9
1
|
|
919
|
|
|
‡a
possiblerecurrenceofprimarysclerosingcholangitisfollowinglivingrelatedlivertransplantationreportofacase
‡A
Possible recurrence of primary sclerosing cholangitis following living-related liver transplantation: report of a case
‡9
1
|
|
919
|
|
|
‡a
postoperativeassessmentinpatientsafterlivertransplantationimagingparametersassociatedwith1yeargraftfailure
‡A
Post-operative assessment in patients after liver transplantation: imaging parameters associated with 1-year graft failure
‡9
1
|
|
919
|
|
|
‡a
posttransplantmetabolicsyndromeinchildrenandadolescentsafterlivertransplantationasystematicreview
‡A
Posttransplant metabolic syndrome in children and adolescents after liver transplantation: a systematic review
‡9
1
|
|
919
|
|
|
‡a
posttransplantationgrowthinpediatricliverrecipients
‡A
Posttransplantation growth in pediatric liver recipients
‡9
1
|
|
919
|
|
|
‡a
posttransplantationlymphoproliferativedisordersinpediatricpatientsundergoinglivertransplantation
‡A
Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation
‡9
1
|
|
919
|
|
|
‡a
potentialroleofthedonorinhepatocellularcarcinomarecurrenceafterlivertransplantation
‡A
Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation
‡9
1
|
|
919
|
|
|
‡a
preexistingmelanomaandhematologicalmalignanciesprognosisandtimingtosolidorgantransplantationaconsensusexpertopinionstatement
‡A
Pre-Existing Melanoma and Hematological Malignancies, Prognosis and Timing to Solid Organ Transplantation: A Consensus Expert Opinion Statement
‡9
1
|
|
919
|
|
|
‡a
pretransplantsolidorganmalignancyandorgantransplantcandidacyaconsensusexpertopinionstatement
‡A
Pre-Transplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement
‡9
1
|
|
919
|
|
|
‡a
predictingbiliarycomplicationsinrightlobelivertransplantrecipientsaccordingtodistancebetweendonorsbileductandcorrespondinghepaticartery
‡A
Predicting biliary complications in right lobe liver transplant recipients according to distance between donor's bile duct and corresponding hepatic artery
‡9
1
|
|
919
|
|
|
‡a
predictingoutcomesonthelivertransplantwaitinglistintheunitedstatesaccountingforlargeregionalvariationinorganavailabilityandpriorityallocationpoints
‡A
Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points.
‡9
1
|
|
919
|
|
|
‡a
predictingrecidivismafterorthotopiclivertransplantationforalcoholicliverdisease
‡A
Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease.
‡9
1
|
|
919
|
|
|
‡a
predictionofsurvivalafterliverretransplantationforlategraftfailurebasedonpreoperativeprognosticscores
‡A
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores
‡9
1
|
|
919
|
|
|
‡a
predictorsassociatedwithterminalrenalfunctionindeceasedorgandonorsintheintensivecareunit
‡A
Predictors associated with terminal renal function in deceased organ donors in the intensive care unit
‡9
1
|
|
919
|
|
|
‡a
predictorsoflowriskfordropoutfromthelivertransplantwaitinglistforhepatocellularcarcinomainlongwaittimeregionsimplicationsfororganallocation
‡A
Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation
‡9
1
|
|
919
|
|
|
‡a
predictorsofthecostoflivertransplantation
‡A
Predictors of the cost of liver transplantation
‡9
1
|
|
919
|
|
|
‡a
predictorsofultrasoundfailuretodetecthepatocellularcarcinoma
‡A
Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma
‡9
1
|
|
919
|
|
|
‡a
preoperativeautologousbloodcollectioninadultlivingliverdonorsarewewastingdonorbloodandincreasingexposuretorisk
‡A
Preoperative Autologous Blood Collection in Adult Living Liver Donors: Are We Wasting Donor Blood and Increasing Exposure to Risk?
‡9
1
|
|
919
|
|
|
‡a
pretransplantseverehepaticencephalopathyperitransplantsodiumandpostlivertransplantationmorbidityandmortality
‡A
Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality
‡9
1
|
|
919
|
|
|
‡a
prioritizationofpatientswithlivercancerwithinthemeldsystem
‡A
Prioritization of patients with liver cancer within the MELD system
‡9
1
|
|
919
|
|
|
‡a
projectedfutureincreaseinaginghepatitis100virusinfectedlivertransplantcandidatesapotentialeffectofhepatocellularcarcinoma
‡A
Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma
‡9
1
|
|
919
|
|
|
‡a
prolongedcoldischemiatimeobviatesthebenefitsof0hlamismatchesinrenaltransplantation
‡A
Prolonged cold ischemia time obviates the benefits of 0 HLA mismatches in renal transplantation
‡9
1
|
|
919
|
|
|
‡a
prophylaxisinlivertransplantrecipientsusingafixeddosingscheduleofhepatitisbimmunoglobulin
‡A
Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
‡9
1
|
|
919
|
|
|
‡a
prospectivephase2trialofdrugelutingbeadchemoembolizationforlivertransplantcandidateswithhepatocellularcarcinomaandmarginalhepaticreserve
‡A
Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve
‡9
1
|
|
919
|
|
|
‡a
pulmonaryhypertensionassociatedwithliverdiseaseisnotreversibleafterlivertransplantation
‡A
Pulmonary hypertension associated with liver disease is not reversible after liver transplantation
‡9
1
|
|
919
|
|
|
‡a
quantifyingtheriskofincompatiblekidneytransplantationamulticenterstudy
‡A
Quantifying the risk of incompatible kidney transplantation: a multicenter study.
‡9
1
|
|
919
|
|
|
‡a
raceethnicityisassociatedwithabononidenticallivertransplantationintheunitedstates
‡A
Race/ethnicity is associated with ABO-nonidentical liver transplantation in the United States
‡9
1
|
|
919
|
|
|
‡a
rapidinfusiontechniqueasasafealternativetovenovenousbypassinorthotopiclivertransplant
‡A
Rapid infusion technique as a safe alternative to veno-venous bypass in orthotopic liver transplant
‡9
1
|
|
919
|
|
|
‡a
rapidinfusiontechniqueasasafealternativetovenovenousbypassinorthotopiclivertransplanttx
‡A
Rapid infusion technique as a safe alternative to veno-venous bypass in orthotopic liver transplant (TX).
‡9
1
|
|
919
|
|
|
‡a
recurrentandacquiredhepatitis100viralinfectioninlivertransplantrecipients
‡A
Recurrent and acquired hepatitis C viral infection in liver transplant recipients
‡9
1
|
|
919
|
|
|
‡a
reducinginfectiontransmissioninsolidorgantransplantationthroughdonornucleicacidtestingacosteffectivenessanalysis
‡A
Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis
‡9
1
|
|
919
|
|
|
‡a
reducingtheshortageoftransplantkidneysalostopportunityfortheushealthresourcesandservicesadministrationhrsa
‡A
Reducing the Shortage of Transplant Kidneys: A Lost Opportunity for the US Health Resources and Services Administration (HRSA)
‡9
1
|
|
919
|
|
|
‡a
removingdisincentivestokidneydonationaquantitativeanalysis
‡A
Removing Disincentives to Kidney Donation: A Quantitative Analysis
‡9
1
|
|
919
|
|
|
‡a
replytoltehep17
‡A
Reply (to LTE HEP-17-2332).
‡9
1
|
|
919
|
|
|
‡a
reportofanationalconferenceonliverallocationinpatientswithhepatocellularcarcinomaintheunitedstates
‡A
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States
‡9
1
|
|
919
|
|
|
‡a
reportofthecrystalcitymeetingtomaximizetheuseoforgansrecoveredfromthecadaverdonor
‡A
Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor
‡9
1
|
|
919
|
|
|
‡a
responsetoclinicalassessmentsofhealthstatusasapotentialmarkertoidentifypatientswhoaretoosicktoundergotransplantation
‡A
Response to clinical assessments of health status as a potential marker to identify patients who are too sick to undergo transplantation
‡9
1
|
|
919
|
|
|
‡a
responsetolettertotheeditors
‡A
Response to letter to the editors
‡9
1
|
|
919
|
|
|
‡a
retransplantationafterlivingdonorlivertransplantationdatafromtheadulttoadultlivingdonorlivertransplantationstudya2all
‡A
Retransplantation After Living Donor Liver Transplantation: Data from the Adult to Adult Living Donor Liver Transplantation Study (A2ALL)
‡9
1
|
|
919
|
|
|
‡a
reversalofchronicrejectionaftertreatmentfailurewithfk506andrs61443
‡A
Reversal of chronic rejection after treatment failure with FK506 and RS61443
‡9
1
|
|
919
|
|
|
‡a
rexshuntpreoperativeimagingdiagnosticcapabilityofimagingmodalities
‡A
Rex shunt preoperative imaging: diagnostic capability of imaging modalities
‡9
1
|
|
919
|
|
|
‡a
riskfactorsforlivertransplantwaitlistdropoutinpatientswithhepatocellularcarcinoma
‡A
Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma
‡9
1
|
|
919
|
|
|
‡a
risksassociatedwithconversionofstablepatientsafterlivertransplantationtothemicroemulsionformulationofcyclosporine
‡A
Risks associated with conversion of stable patients after liver transplantation to the microemulsion formulation of cyclosporine
‡9
1
|
|
919
|
|
|
‡a
safetyofcardiaccatheterizationinpatientswithendstageliverdiseaseawaitinglivertransplantation
‡A
Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation
‡9
1
|
|
919
|
|
|
‡a
safetytolerabilityandefficacyofeverolimusindenovolivertransplantrecipients12and36monthresults
‡A
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results
‡9
1
|
|
919
|
|
|
‡a
serumsodiumpredictsmortalityinpatientslistedforlivertransplantation
‡A
Serum sodium predicts mortality in patients listed for liver transplantation
‡9
1
|
|
919
|
|
|
‡a
settingrulesforthesandboxaresponsetosuccessfullysharingthesandboxaperspectiveoncombineddcdliverandheartdonorprocurement
‡A
Setting rules for the sandbox: A response to "Successfully sharing the sandbox: A perspective on combined DCD liver and heart donor procurement"
‡9
1
|
|
919
|
|
|
‡a
severityofliverdiseaseinlivertransplantationrecipientswithhepatitis100virusinfectionrelationshiptogenotypeandlevelofviremia
‡A
Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia
‡9
1
|
|
919
|
|
|
‡a
shortcourseofpostoperativehepatitisbimmunoglobulinplusantiviralspreventsreinfectionoflivertransplantrecipients
‡A
Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients
‡9
1
|
|
919
|
|
|
‡a
shouldpatientswithnafldnashbesurveyedforhcc
‡A
Should Patients With NAFLD/NASH Be Surveyed for HCC?
‡9
1
|
|
919
|
|
|
‡a
similarclinicalpresentationofneurotoxicityfollowingfk506andcyclosporineinalivertransplantrecipient
‡A
Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient
‡9
1
|
|
919
|
|
|
‡a
sir2006annualmeetingfilmpanelcasebuddchiarisyndromeinapatientwithcogansyndrome
‡A
SIR 2006 Annual Meeting Film Panel Case: Budd-Chiari syndrome in a patient with Cogan syndrome.
‡9
1
|
|
919
|
|
|
‡a
sirolimusprolongsrecoveryfromdelayedgraftfunctionaftercadavericrenaltransplantation
‡A
Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation
‡9
1
|
|
919
|
|
|
‡a
smallbowelmotilityfollowingmajorintraabdominalsurgerytheeffectsofopiatesandrectalcisapride
‡A
Small bowel motility following major intra-abdominal surgery: the effects of opiates and rectal cisapride
‡9
1
|
|
919
|
|
|
‡a
solvingtheorganshortagecrisisthe7annualamericansocietyoftransplantsurgeonsstateoftheartwintersymposium
‡A
Solving the organ shortage crisis: the 7th annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium
‡9
1
|
|
919
|
|
|
‡a
splitlivertransplantationandpediatricwaitlistmortalityintheunitedstatespotentialforimprovement
‡A
Split Liver Transplantation and Pediatric Waitlist Mortality in the United States: Potential for Improvement
‡9
1
|
|
919
|
|
|
‡a
splitlivertransplantationisutilizedinfrequentlyandconcentratedatfewtransplantcentersintheunitedstates
‡A
Split liver transplantation is utilized infrequently and concentrated at few transplant centers in the United States
‡9
1
|
|
919
|
|
|
‡a
standardsequentialimmunosuppressionwithminnesotaantilymphoblastglobulinandcyclosporinevsfk506acomparisonofearlynephrotoxicity
‡A
Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity
‡9
1
|
|
919
|
|
|
‡a
stimulusfororgandonationasurveyoftheamericansocietyoftransplantsurgeonsmembership
‡A
Stimulus for organ donation: a survey of the American Society of Transplant Surgeons membership
‡9
1
|
|
919
|
|
|
‡a
strategiesfortoleranceinductionpotentialapplicationsinlivingdonorlivertransplantation
‡A
Strategies for tolerance induction: potential applications in living donor liver transplantation
‡9
1
|
|
919
|
|
|
‡a
summaryreportofanationalconferenceevolvingconceptsinliverallocationinthemeldandpelderadecember82003washington600usa
‡A
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA.
‡9
1
|
|
919
|
|
|
‡a
superselectivearterialembolizationinthelivertransplantrecipientasafetreatmentforhemobiliacausedbypercutaneoustranshepaticbiliarydrainage
‡A
Superselective arterial embolization in the liver transplant recipient: a safe treatment for hemobilia caused by percutaneous transhepatic biliary drainage
‡9
1
|
|
919
|
|
|
‡a
surgicalanatomyoftheleftlateralsegmentasappliedtolivingdonorandsplitlivertransplantationaclinicopathologicstudy
‡A
Surgical anatomy of the left lateral segment as applied to living-donor and split-liver transplantation: a clinicopathologic study
‡9
1
|
|
943
|
|
|
‡a
201x
‡A
2014
‡9
3
|
|
996
|
|
|
‡2
ISNI|0000000400115844
|
|
996
|
|
|
‡2
ISNI|0000000392680017
|
|
996
|
|
|
‡2
NLA|000035954678
|
|
996
|
|
|
‡2
ISNI|0000000360980488
|
|
996
|
|
|
‡2
RERO|A022775328
|
|
996
|
|
|
‡2
ISNI|0000000487183398
|
|
996
|
|
|
‡2
LC|no2013103721
|
|
996
|
|
|
‡2
LC|n 84028081
|
|
996
|
|
|
‡2
J9U|987007313187405171
|
|
996
|
|
|
‡2
LC|no2012029402
|
|
996
|
|
|
‡2
LC|n 96019718
|
|
996
|
|
|
‡2
RERO|A009036609
|
|
996
|
|
|
‡2
BIBSYS|90670693
|
|
996
|
|
|
‡2
SUDOC|281201412
|
|
996
|
|
|
‡2
BNF|15584387
|
|
996
|
|
|
‡2
LC|n 98032376
|
|
996
|
|
|
‡2
DNB|1187984450
|
|
996
|
|
|
‡2
BNF|13329938
|
|
996
|
|
|
‡2
BIBSYS|15000534
|
|
996
|
|
|
‡2
BIBSYS|99066888
|
|
996
|
|
|
‡2
LC|n 86073565
|
|
996
|
|
|
‡2
ISNI|0000000024771839
|
|
996
|
|
|
‡2
SUDOC|027103536
|
|
996
|
|
|
‡2
LC|nb2014020834
|
|
996
|
|
|
‡2
ISNI|0000000039164249
|
|
996
|
|
|
‡2
DNB|1246325365
|
|
996
|
|
|
‡2
BNF|14962383
|
|
996
|
|
|
‡2
ISNI|0000000021570169
|
|
996
|
|
|
‡2
DNB|1128660318
|
|
996
|
|
|
‡2
DNB|12279060X
|
|
996
|
|
|
‡2
LC|no 98091022
|
|
996
|
|
|
‡2
NII|DA0073198X
|
|
996
|
|
|
‡2
NII|DA01272039
|
|
996
|
|
|
‡2
CAOONL|ncf10707617
|
|
996
|
|
|
‡2
LC|nr2004025443
|
|
996
|
|
|
‡2
NTA|126705925
|
|
996
|
|
|
‡2
SUDOC|19022228X
|
|
996
|
|
|
‡2
J9U|987007332100805171
|
|
996
|
|
|
‡2
ISNI|0000000044144859
|
|
996
|
|
|
‡2
LC|no2012109299
|
|
996
|
|
|
‡2
LC|n 96800146
|
|
996
|
|
|
‡2
SUDOC|070468923
|
|
996
|
|
|
‡2
LC|nr 93033451
|
|
996
|
|
|
‡2
LC|nr 93033450
|
|
996
|
|
|
‡2
CAOONL|ncf12098595
|
|
996
|
|
|
‡2
B2Q|0000288233
|
|
996
|
|
|
‡2
NLA|000035683664
|
|
996
|
|
|
‡2
LC|n 79061296
|
|
996
|
|
|
‡2
J9U|987012579156205171
|
|
996
|
|
|
‡2
RERO|A003751262
|
|
996
|
|
|
‡2
J9U|987007458314205171
|
|
996
|
|
|
‡2
LIH|LNB:V-264934;=BO
|
|
996
|
|
|
‡2
ISNI|0000000501134833
|
|
996
|
|
|
‡2
NKC|js20051017056
|
|
996
|
|
|
‡2
J9U|987007312972305171
|
|
996
|
|
|
‡2
SUDOC|188264841
|
|
996
|
|
|
‡2
DNB|133374971
|
|
996
|
|
|
‡2
LC|n 88623560
|
|
996
|
|
|
‡2
ISNI|0000000108448502
|
|
996
|
|
|
‡2
LNB|LNC10-000063945
|
|
996
|
|
|
‡2
ISNI|0000000047031083
|
|
996
|
|
|
‡2
BIBSYS|90806853
|
|
996
|
|
|
‡2
PLWABN|9814281998405606
|
|
996
|
|
|
‡2
JPG|500243507
|
|
996
|
|
|
‡2
ISNI|0000000117566957
|
|
996
|
|
|
‡2
BIBSYS|90611580
|
|
996
|
|
|
‡2
ISNI|0000000037227971
|
|
996
|
|
|
‡2
DNB|1046457659
|
|
996
|
|
|
‡2
SUDOC|270927301
|
|
996
|
|
|
‡2
LIH|LNB:7_h_M;=BS
|
|
996
|
|
|
‡2
RERO|A000138286
|
|
996
|
|
|
‡2
LC|no2002050003
|
|
996
|
|
|
‡2
ISNI|0000000392182798
|
|
996
|
|
|
‡2
DNB|128712546
|
|
996
|
|
|
‡2
SUDOC|084107812
|
|
996
|
|
|
‡2
BNF|12179634
|
|
996
|
|
|
‡2
NSK|000375684
|
|
996
|
|
|
‡2
LC|n 86855922
|
|
996
|
|
|
‡2
NTA|112679137
|
|
996
|
|
|
‡2
LC|nb2010018690
|
|
996
|
|
|
‡2
DNB|1136590382
|
|
996
|
|
|
‡2
NUKAT|n 99068005
|
|
996
|
|
|
‡2
DNB|1038563062
|
|
996
|
|
|
‡2
LC|n 79016371
|
|
996
|
|
|
‡2
SUDOC|265749301
|
|
996
|
|
|
‡2
BNC|981058515022506706
|
|
996
|
|
|
‡2
BIBSYS|90127093
|
|
996
|
|
|
‡2
ISNI|0000000451168081
|
|
996
|
|
|
‡2
LC|n 94061298
|
|
996
|
|
|
‡2
PLWABN|9813127686205606
|
|
996
|
|
|
‡2
LC|no2009053300
|
|
996
|
|
|
‡2
ICCU|TO0V026889
|
|
996
|
|
|
‡2
ISNI|0000000044890595
|
|
996
|
|
|
‡2
NII|DA06980896
|
|
996
|
|
|
‡2
LC|nb2010018671
|
|
996
|
|
|
‡2
BIBSYS|4068937
|
|
996
|
|
|
‡2
LC|nb2010017838
|
|
996
|
|
|
‡2
ERRR|12469920
|
|
996
|
|
|
‡2
CAOONL|ncf10956529
|
|
996
|
|
|
‡2
ISNI|0000000030317595
|
|
996
|
|
|
‡2
NII|DA04192184
|
|
996
|
|
|
‡2
NII|DA08473833
|
|
996
|
|
|
‡2
CAOONL|ncf10716398
|
|
996
|
|
|
‡2
BNE|XX1151032
|
|
996
|
|
|
‡2
LC|n 79020863
|
|
996
|
|
|
‡2
LC|nr 90025269
|
|
996
|
|
|
‡2
NKC|mzk20191058032
|
|
996
|
|
|
‡2
SUDOC|067643108
|
|
996
|
|
|
‡2
ISNI|0000000053701880
|
|
996
|
|
|
‡2
DNB|1318570565
|
|
996
|
|
|
‡2
BIBSYS|90627766
|
|
996
|
|
|
‡2
J9U|987007441232005171
|
|
996
|
|
|
‡2
DNB|143503456
|
|
996
|
|
|
‡2
ISNI|0000000030722662
|
|
996
|
|
|
‡2
LC|no2019091820
|
|
996
|
|
|
‡2
N6I|vtls000330907
|
|
996
|
|
|
‡2
J9U|987007348576005171
|
|
996
|
|
|
‡2
LC|n 95075605
|
|
996
|
|
|
‡2
NYNYRILM|201670
|
|
996
|
|
|
‡2
SUDOC|032698100
|
|
996
|
|
|
‡2
LC|n 2011077735
|
|
996
|
|
|
‡2
DNB|1089839618
|
|
996
|
|
|
‡2
ISNI|0000000109353011
|
|
996
|
|
|
‡2
NYNYRILM|201675
|
|
996
|
|
|
‡2
LC|no2019006676
|
|
996
|
|
|
‡2
ISNI|0000000044436106
|
|
996
|
|
|
‡2
BAV|495_303996
|
|
996
|
|
|
‡2
LC|no2005048639
|
|
996
|
|
|
‡2
LC|n 2008023116
|
|
996
|
|
|
‡2
NUKAT|n 2004095588
|
|
996
|
|
|
‡2
ISNI|0000000029296985
|
|
996
|
|
|
‡2
LC|n 96108573
|
|
996
|
|
|
‡2
ISNI|0000000499954735
|
|
996
|
|
|
‡2
LC|n 86830648
|
|
996
|
|
|
‡2
SUDOC|13004119X
|
|
996
|
|
|
‡2
RERO|A006083406
|
|
996
|
|
|
‡2
SELIBR|252801
|
|
996
|
|
|
‡2
NUKAT|n 2016149135
|
|
996
|
|
|
‡2
ISNI|0000000374569649
|
|
996
|
|
|
‡2
DNB|172989191
|
|
996
|
|
|
‡2
DNB|107470147X
|
|
996
|
|
|
‡2
LC|no 99020426
|
|
996
|
|
|
‡2
NUKAT|n 2004073836
|
|
996
|
|
|
‡2
BNF|16560212
|
|
996
|
|
|
‡2
NUKAT|n 00056638
|
|
996
|
|
|
‡2
J9U|987007463394305171
|
|
996
|
|
|
‡2
LC|no2021138409
|
|
996
|
|
|
‡2
ISNI|0000000420512177
|
|
996
|
|
|
‡2
LC|nb2010020764
|
|
996
|
|
|
‡2
NUKAT|n 94303288
|
|
996
|
|
|
‡2
SELIBR|217992
|
|
996
|
|
|
‡2
NII|DA14855856
|
|
996
|
|
|
‡2
RERO|A022960233
|
|
996
|
|
|
‡2
LNB|LNC10-000189710
|
|
996
|
|
|
‡2
NII|DA05600774
|
|
996
|
|
|
‡2
PLWABN|9810555922905606
|
|
996
|
|
|
‡2
NTA|22975113X
|
|
996
|
|
|
‡2
ISNI|000000004927517X
|
|
996
|
|
|
‡2
ISNI|0000000108452376
|
|
996
|
|
|
‡2
LC|nr 89007990
|
|
996
|
|
|
‡2
J9U|987007267169905171
|
|
996
|
|
|
‡2
NTA|40389719X
|
|
996
|
|
|
‡2
CAOONL|ncf11328127
|
|
996
|
|
|
‡2
ISNI|0000000082121308
|
|
996
|
|
|
‡2
BNF|12751369
|
|
996
|
|
|
‡2
LC|no2002114739
|
|
996
|
|
|
‡2
NTA|33971171X
|
|
996
|
|
|
‡2
ISNI|0000000031633119
|
|
996
|
|
|
‡2
NUKAT|n 02724778
|
|
996
|
|
|
‡2
NUKAT|n 96103617
|
|
996
|
|
|
‡2
NKC|jx20111212040
|
|
996
|
|
|
‡2
LC|n 93002777
|
|
996
|
|
|
‡2
DNB|1061693805
|
|
996
|
|
|
‡2
LC|n 87824415
|
|
996
|
|
|
‡2
NYNYRILM|46584
|
|
996
|
|
|
‡2
ISNI|0000000108556845
|
|
996
|
|
|
‡2
ISNI|0000000086701713
|
|
996
|
|
|
‡2
BIBSYS|7038642
|
|
996
|
|
|
‡2
BIBSYS|90545430
|
|
996
|
|
|
‡2
NUKAT|n 2013194397
|
|
996
|
|
|
‡2
LNB|LNC10-000189708
|
|
996
|
|
|
‡2
LC|n 87929826
|
|
996
|
|
|
‡2
BIBSYS|3115568
|
|
996
|
|
|
‡2
LC|n 85133016
|
|
996
|
|
|
‡2
LNB|LNC10-000189706
|
|
996
|
|
|
‡2
LNB|LNC10-000189707
|
|
996
|
|
|
‡2
DNB|1089306148
|
|
996
|
|
|
‡2
BIBSYS|1512647516609
|
|
996
|
|
|
‡2
LC|n 86053683
|
|
996
|
|
|
‡2
ISNI|0000000051290416
|
|
996
|
|
|
‡2
LC|n 79005757
|
|
996
|
|
|
‡2
JPG|500069454
|
|
996
|
|
|
‡2
ISNI|0000000115067679
|
|
996
|
|
|
‡2
SUDOC|06939976X
|
|
996
|
|
|
‡2
BNF|12367830
|
|
996
|
|
|
‡2
PLWABN|9810688941505606
|
|
996
|
|
|
‡2
CAOONL|ncf11191270
|
|
996
|
|
|
‡2
NKC|jx20110824021
|
|
996
|
|
|
‡2
LC|n 88607344
|
|
996
|
|
|
‡2
SUDOC|167307266
|
|
996
|
|
|
‡2
RERO|A003751273
|
|
996
|
|
|
‡2
BNE|XX826814
|
|
996
|
|
|
‡2
LC|n 92097298
|
|
996
|
|
|
‡2
LC|n 85827510
|
|
996
|
|
|
‡2
RERO|A003751269
|
|
996
|
|
|
‡2
RERO|A003751268
|
|
996
|
|
|
‡2
NDL|00663655
|
|
996
|
|
|
‡2
ISNI|0000000389719654
|
|
996
|
|
|
‡2
LC|n 2015071435
|
|
996
|
|
|
‡2
RERO|A003751263
|
|
996
|
|
|
‡2
RERO|A003751261
|
|
996
|
|
|
‡2
B2Q|0001441515
|
|
996
|
|
|
‡2
RERO|A003751267
|
|
996
|
|
|
‡2
RERO|A003751266
|
|
996
|
|
|
‡2
LC|nr 93033457
|
|
996
|
|
|
‡2
RERO|A003751264
|
|
996
|
|
|
‡2
CAOONL|ncf10987471
|
|
996
|
|
|
‡2
ISNI|0000000063589837
|
|
996
|
|
|
‡2
J9U|987007307139205171
|
|
996
|
|
|
‡2
LC|no2007156702
|
|
996
|
|
|
‡2
LC|nb2015002013
|
|
996
|
|
|
‡2
NLA|000035455424
|
|
996
|
|
|
‡2
ISNI|0000000039650108
|
|
996
|
|
|
‡2
ISNI|0000000041916251
|
|
996
|
|
|
‡2
PLWABN|9810600036005606
|
|
996
|
|
|
‡2
LC|nb2018016262
|
|
996
|
|
|
‡2
BNE|XX943827
|
|
996
|
|
|
‡2
LC|no2020088750
|
|
996
|
|
|
‡2
ISNI|0000000074147399
|
|
996
|
|
|
‡2
NII|DA12700837
|
|
996
|
|
|
‡2
LC|no2013001184
|
|
996
|
|
|
‡2
RERO|A018529360
|
|
996
|
|
|
‡2
SUDOC|087654466
|
|
996
|
|
|
‡2
LC|n 83134058
|
|
996
|
|
|
‡2
BNF|12287523
|
|
996
|
|
|
‡2
NDL|00473866
|
|
996
|
|
|
‡2
ISNI|0000000035205912
|
|
996
|
|
|
‡2
ISNI|0000000393038501
|
|
996
|
|
|
‡2
BNF|15061037
|
|
996
|
|
|
‡2
SELIBR|261604
|
|
996
|
|
|
‡2
SUDOC|032932901
|
|
996
|
|
|
‡2
LC|n 94042124
|
|
996
|
|
|
‡2
LC|n 88619939
|
|
996
|
|
|
‡2
DNB|172523923
|
|
996
|
|
|
‡2
ISNI|0000000074151558
|
|
996
|
|
|
‡2
LNB|LNC10-000055710
|
|
996
|
|
|
‡2
CAOONL|ncf11570523
|
|
996
|
|
|
‡2
LC|nr 93015069
|
|
996
|
|
|
‡2
DNB|142130486
|
|
996
|
|
|
‡2
LC|n 84000657
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
